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Introduction: This study aimed to investigate the effects of dextromethorphan (DM) or dextromethorphan/qui-
nidine (DM/Q) against pentylenetetrazole (PTZ)- induced seizure threshold in mice and the probable involve-
ment of N-methyl D-aspartate (NMDA), sigma-1 and serotonin 1A (5-HT1A) receptors.
Material and methods: NMRI male mice (25–30 g) received quinidine (10, 20, and 30 mg/kg), DM (5, 10, 25, and
50 mg/kg) or DM/Q (10/20, 25/20, and 50/20 mg/kg), 30 min before the infusion of PTZ. ketamine (1 and 5
mg/kg), BD-1047 (2.5 and 5 mg/kg) or WAY-100635 (0.5 and 1 mg/kg) were administrated as pre-treatment 30
min before the selected dose of DM/Q. Seizures were induced by intravenous PTZ infusion. All data were pre-
sented as means± S.E.M. One-way ANOVA test was used to determine statistical significance (p<0.05).
Results: DM (25 and 50 mg/kg) significantly increased PTZ- induced seizure threshold. DM/Q at doses of 10/20
and 25/20 mg/kg had anticonvulsant effect, while at a dose of 50/20 mg/kg attenuated anticonvulsant effect of
DM 50 mg/kg. Ketamine (5 mg/kg) or WAY-100635 (1 mg/kg) potentiated, while BD-1047 (2.5 and 5 mg/kg)
attenuated the anticonvulsant effect of DM/Q 10/20 mg/kg.
Conclusion: The results of present study demonstrate that combination with quinidine potentiates the antic-
onvulsant effect of DM at lower doses, while attenuates it at higher dose. Meanwhile, the effects of DM/Q on
seizure activity likely involve an interaction with NMDA, the sigma-1 or the 5-HT1A receptor which may be
secondary to the elevation of DM levels.
1. Introduction
Dextromethorphan (DM) is a non-opioid morphinan derivative [1].
At therapeutic doses, DM has negligible side effects; however, at high
doses, DM produces a complex pharmacological profile [2,3]. DM in-
teracts with N-methyl-D-aspartate (NMDA), sigma-1, and serotonin [5-
hydroxytryptamine (5-HT)] receptors [4,5]. Some clinical reports [6,7]
and animal studies [8,9] show that DM has a proconvulsant effect.
Meanwhile, the anticonvulsant effect of DM has been established in
different types of animal seizure models [5,10,11]. The anticonvulsant
effects of DM appears to be due to antagonizing NMDA receptors [12]
or activation of sigma-1 receptors [1]. A combination of DM with
quinidine, referred to DM/Q, increases the plasma level and bioavail-
ability of DM in the brain. Quinidine inhibits the cytochrome P450 2D6
enzyme (CYP2D6) and P-glycoprotein (P-gp) [3,13]. DM/Q increases
the ratio of circulating free DM to dextrophan (DX), the main meta-
bolite of DM, up to 14-fold. To the best of our knowledge, there is no
study regarding the effect of DM/Q on animal models of seizure. This
study aimed to find out the effects of acute administration of quinidine,
DM and DM/Q on pentylenetetrazole (PTZ)- induced clonic and tonic
seizure thresholds in mice. Also, the role of NMDA, the sigma-1 and the
serotonergic 5-HT1A receptor were investigated too.
2. Materials and methods
2.1. Animals
Male mice of the NMRI strain (n = 7 in each group), bred in the
animal house of the Physiology Research Centre, Kashan University of
Medical Sciences (age 5–6 weeks and weight 25–30 g) were used.
Animals were housed (seven animals per cage) in standard poly-
propylene cages, at a constant temperature of 22±2 and humidity of
50–55 %, with automatically controlled 12/12 h light/dark cycles. All
animals were fed a regular mice chow and water ad libitum. All ex-
periments were performed by the guide for the Care and Use of
Laboratory Animals (National Institutes of Health Publication No. 85-
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23, revised 1985) and were approved by the Research and Ethics
Committee of Kashan University of Medical Sciences (ethics code: I.R
KAUMS.MEDNT.REC.1397.22), Kashan, Iran.
2.2. Drugs
PTZ, quinidine, DM, ketamine (NMDA receptor antagonist), BD-
1047 (a selective sigma-1 receptor antagonist) and WAY-100635 (a
specific 5-HT1A receptor antagonist) were chemicals and drugs, which
were used in this study. PTZ was purchased from Sigma (USA) and all
the other drugs were supplied from Tocris (UK). All the mentioned
drugs, except PTZ, were injected via intraperitoneal (i.p.) route in a
volume of 5 mL/kg of body weight. Drug doses used in this study were
based on the results of previous studies [14,15].
2.3. Experiments
In experiment 1 (including 11 groups), animals received different
doses of quinidine (10, 20, and 30 mg/kg, i.p.), DM (5, 10, 25, and 50
mg/kg, i.p.) or DM/Q (5/20, 10/20, 25/20, and 50/20 mg/kg, i.p.) 30
min before determining PTZ-induced seizure threshold. Based on our
experiments, quinidine at a dose of 20 mg/kg and DM at a dose of 10
mg/kg were used in later experiments.
In experiment 2 (including 6 groups), mice were acutely admini-
strated with different doses of ketamine (1 and 5 mg/kg, i.p.), BD-1047
(2.5 and 5 mg/kg, i.p.) or WAY-100635 (0.5 and 1 mg/kg, i.p.) 60 min
before determining PTZ-induced seizure threshold.
In experiments 3 (including 6 groups), we examined the effect of
pre-treatment with the same doses of ketamine (1 and 5 mg/kg, i.p.),
BD-1047 (2.5 and 5 mg/kg, i.p.) or WAY-100635 (0.5 and 1 mg/kg,
i.p.) 30 min before administration of the selected dose of DM/Q (10/20
mg/kg, i.p.). In all pre-treatment groups, PTZ- induced seizure
threshold was determined 30 min after DM/Q administration.
Control animals (including 4 groups) received saline, dimethyl
sulfoxide (DMSO), saline + DM/Q or DMSO + DM/Q, upon the ex-
perimental plan.
2.4. Seizure induction
Briefly, a 30-gauge dental needle attached to a polyethylene (PE)
tubing was inserted to the lateral vein of each mouse. The PTZ solution
(5 mg/mL) was then infused into the tail vein of the freely moving
mouse at a constant rate of 0.5 mL/min using a syringe pump (Top,
Japan). The times were recorded (in seconds) from the start of the in-
fusion to the appearance of myoclonic twitch (MC twitch) and tonic
hind limb extension (THE). The recorded times were then converted to
mg/kg PTZ for each mouse depends on PTZ dose and time-related
[14,16].
2.5. Statistical analysis
All results were expressed as mean values SEM. Statistical analysis
of the results was done by one-way ANOVA for the seizure thresholds
followed by Tukey’s test for multiple comparisons. Differences were
considered significant if the P-value were less than 0.05.
3. Results
3.1. Effect of different doses of quinidine on the PTZ-induced seizure
threshold
Fig. 1 illustrates the effect of quinidine at different doses (10, 20,
and 30 mg/kg) on the threshold dose for the onset to MC twitch and
THE. All doses of quinidine were ineffective in changing the seizure
threshold of PTZ for the onset to MC twitch. Considering THE, one-way
ANOVA revealed a significant effect (F3,24 = 4.34, P = 0.014). Post
hoc analysis showed that quinidine at a dose of 30 mg/kg significantly
increased the threshold dose for the onset to THE, compared to the
saline-treated control group (p<0.05).
3.2. Effect of different doses of DM or DM/Q on the PTZ-induced seizure
threshold
Considering MC twitch (Fig. 2A), one-way ANOVA revealed a sig-
nificant effect (F8,54 = 5.49, P = 0.000). Post hoc analysis showed that
DM at doses of 25 and 50 mg/kg significantly increased the threshold
dose for the onset to MC twitch, (p< 0.05 and p<0.01 respectively).
Meanwhile, DM/Q at a dose of 50 mg/kg significantly decreased the
threshold dose for the onset to MC twitch compared to 50 mg/kg of DM
alone group (p< 0.001).
Considering THE (Fig. 2.B), one-way ANOVA revealed a significant
effect (F8,54 = 114.46, P = 0.000). Post hoc analysis showed that
compared to the saline-treated control group, DM (25 and 50 mg/kg) or
DM/Q (10/20, 25/20 and 50/20 mg/kg) significantly increased
threshold dose for the onset to THE (p<0.001). Compared to DM alone
groups, DM/Q at doses of 10/20 and 25/20 mg/kg significantly in-
creased the threshold dose for the onset to THE (p<0.01), while at a
dose of 50/20 mg/kg significantly decreased it (p< 0.001).
3.3. Effect of ketamine, an NMDA receptor antagonist, alone or as pre-
treatment before DM/Q (10/20 mg/kg) on the PTZ-induced seizure
threshold
Considering MC twitch (Fig. 3A), one-way ANOVA revealed a sig-
nificant effect (F5,36 = 12, P = 0.000). Post hoc analysis showed that
pre-treatment with ketamine at doses of 1 and 5 mg/kg significantly
decreased the threshold dose for the onset to MC twitch, compared to
saline + DM/Q (10/20 mg/kg) control group (p<0.05 and p<0.001,
respectively).
Considering THE (Fig. 3.B), one-way ANOVA revealed a significant
effect (F5,36 = 110, P = 0.000). Compared to saline + DM/Q (10/20
mg/kg) control group, post hoc analysis showed that pre-treatment with
ketamine at a dose of 5 mg/kg significantly decreased the threshold
dose for the onset to THE (p<0.001).
3.4. Effect of BD-1047, a selective sigma-1 receptor antagonist, alone or as
pre-treatment before DM/Q (10/20 mg/kg) on the PTZ-induced seizure
threshold
Fig. 4.A shows the effect of acute administration of BD-1047 (2.5
and 5 mg/kg, i.p.) alone or as a pre-treatment before DM/Q (10/20 mg/
kg) on the threshold dose for the onset to MC twitch. One-way ANOVA
did not reveal a significant effect (F5,36 = 2.39, P = 0.056).
Fig. 4.B shows the effect of acute administration of BD-1047 (2.5
and 5 mg/kg, i.p.) alone or as a pre-treatment before DM/Q (10/20 mg/
kg) on the threshold dose for the onset to THE. One-way ANOVA re-
vealed a significant effect (F5,36 = 59.87, P = 0.000). When BD-1047
was administrated alone, post hoc analysis showed that compared to
saline-treated control group, BD-1047 at a dose of 5 mg/kg significantly
decreased threshold dose for the onset to THE (p< 0.05). Compared to
the saline + DM/Q (10/20 mg/kg) control group, pre-treatment with
BD-1047 at doses of 2.5 and 5 mg/kg significantly decreased the
threshold dose for the onset to THE (p<0.001).
3.5. Effect of WAY-100635, a specific 5-HT1A receptor antagonist, alone or
as pre-treatment before DM/Q (10/20 mg/kg) on the PTZ-induced seizure
threshold
Fig. 5.A shows the effect of acute administration of WAY-100635
(0.5 and 1 mg/kg, i.p.) alone or as a pre-treatment before DM/Q (10/20
mg/kg) on the threshold dose for the onset to MC twitch. One-way
ANOVA revealed a significant effect (F5,36 = 5.75, P = 0.001). When
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WAY-100635 was administrated alone, post hoc analysis showed that
pre-treatment with WAY-100635 at a dose of 1 mg/kg significantly
increased the threshold dose for the onset of MC twitch, compared to
DMSO + DM/Q (10/20 mg/kg) control group (p<0.05).
Fig. 5.B shows the effect of acute administration of WAY-100635
(0.5 and 1 mg/kg, i.p.) alone or as a pre-treatment before DM/Q (10/20
mg/kg) on the threshold dose for the onset to THE. One-way ANOVA
revealed a significant effect (F5,36 = 70.39, P = 0.000). When WAY-
100635 was administrated alone, post hoc analysis showed that
compared to DMSO + DM/Q (10/20 mg/kg) control group, pre-treat-
ment with WAY-100635 at a dose of 1 mg/kg significantly increased
threshold dose for the onset to THE (p<0.05).
4. Discussion
The results of the present experiment confirm and extend previous
reports that dextromethorphan (DM) has an anticonvulsant effect.
Moreover, concomitant administration of quinidine (Q) at a dose of 20
Fig. 1. Effect of different doses of quinidine [0 (saline), 10, 20, and 30 mg/kg, i.p.] on the seizure threshold of PTZ to the onset to MC twitch (A) and THE (B).
*P< 0.05 in comparison with the saline-treated control group (mean± S.E.M, n = 7).
Fig. 2. Effect of different doses of DM (5, 10, 25, and 50 mg/kg, i.p.) or DM/Q (5/20, 10/20, 25/20, and 50/20 mg/kg, i.p.) on the seizure threshold of PTZ to the
onset to MC twitch (A) and THE (B). *P< 0.05, **P< 0.01 and ***P< 0.001 in comparison with saline group, ++ P<0.01 and +++ P<0.001 in comparison with
DM group (mean± S.E.M, n = 7).
Fig. 3. Effect of different doses of ketamine (1 and 5 mg/kg, i.p.) alone or as pre-treatment before DM/Q (10/20 mg/kg, i.p.) on the seizure threshold of PTZ to the
onset to MC twitch (A) and THE (B). +P<0.05, +++ P<0.001 in comparison with saline + DM/Q group (mean± S.E.M, n = 7).
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mg/kg with different doses of DM (10, 25, and 50 mg/kg) revealed
different effects on seizure threshold. DM/Q at doses of 10/20 or 25/20
mg/kg increases seizure threshold, while DM/Q at a dose of 50/20 mg/
kg decreases seizure threshold. These results indicate that the effects of
DM on the seizure threshold do not need conversion to the metabolite
DX. Moreover, our results implicate the contribution of NMDA, sigma-1
and serotonin 5HT-1A receptors in the central effect of DM/Q on sei-
zure threshold.
The anticonvulsant effect of quinidine in our study (Fig. 1B) con-
firms the report that quinidine and some other gap junction blockers
protect against seizures [17]. The anticonvulsant effect of quinidine is
likely to be due to the inhibition of p-glycoprotein (P-gp) or CYP2D6
[13], although it needs further investigation. DM level increases as a
result of CYP2D6 or P-gp inhibition in the CNS. Therefore, the differ-
ence between the effects of DM/Q compared to DM appears to be due to
increased levels of DM. The results of clinical studies suggest that DM/Q
stabilizes adequate concentrations of DM by blocking its metabolism
[18–20]. Therefore, it seems that the metabolism of DM to DX is not
necessary for the anticonvulsant effect of DM. On the other hand, our
results showed that a higher dose of DM had a proconvulsant effect.
This finding is in line with the report that high levels of DM have a
procovulsant effect [21].
Our results showed that DM had a more pronounced effect on the
threshold dose to the onset of THE (Fig. 2B) than MC twitch (Fig. 2A).
Previous investigations suggest that the origin of MC twitch is forebrain
(including the cerebrum, the thalamus, the hypothalamus, and the
limbic system), while the origin of THE is hindbrain that is composed of
the medulla, the pons, and the cerebellum [16]. GluN2B subunit has
exclusive distribution in the cerebral cortex and hippocampus, while
GluN1 and GluN2A subunits have a widespread distribution in all part
of the CNS [22,23]. Seizure induction increases the expression of the
GluN2B subunit [24]. Different distribution of the NMDA receptor
subunits may explain why DM has a more pronounced effect on THE
than MC twitch. Given that quinidine increases DM levels, the more
pronounced effect of DM/Q on THE seems convincing (Fig. 3A, B).
The anticonvulsant effect of DM is partly by its inhibitory effect on
NMDA receptors. Therefore, we investigated the effect of pre-treatment
with ketamine before DM/Q 10/20 mg/kg to evaluate the role of NMDA
receptors. The finding that ketamine potentiates the anticonvulsant
effect of DM/Q 10/20 mg/kg suggests the possible involvement of
NMDA receptors.
The anticonvulsant effect of DM/Q appears to involve the activation
of sigma-1 receptors. Recent studies imply the potential therapeutic
effects of sigma-1 receptor agonists as a novel target to treat neurolo-
gical disorders [25–27]. Considering the high-affinity of DM to sigma-1
receptors [28], further studies are needed to investigate the involve-
ment of sigma-1 receptors in the anticonvulsant effect of DM. Despite
previous reports that the sigma-1 receptor has a widespread distribu-
tion in the CNS, the regional distribution of the sigma-1 receptor
showed that locus coeruleus, a nucleus in the pons of the brainstem, had
the highest distribution of the sigma-1 receptor [29]. The highest dis-
tribution of the sigma-1 receptors in the hindbrain may partly explain
why DB-1047 alone or as pre-treatment before DM/Q 10/20 mg/kg
decreases the threshold dose to the onset of THE (Fig. 4B) without effect
on MC twitch (Fig. 4A).
DM promotes 5-HT release, blocks serotonin reuptake and induces
DM-induced serotonergic behaviors by activation of the 5-HT1A re-
ceptor [30]. WAY-100635 at a dose of 1 mg/kg potentiated the
Fig. 4. Effect of different doses of BD-1047 (2.5 and 5 mg/kg, i.p.) alone or as pre-treatment before DM/Q (10/20 mg/kg, i.p.) on the seizure threshold of PTZ to the
onset to MC twitch (A) and THE (B). *P< 0.05 in comparison with saline group, +++ P<0.001 in comparison with saline + DM/Q group (mean± S.E.M, n = 7).
Fig. 5. Effect of different doses of WAY-100635 (0.5 and 1 mg/kg, i.p.) alone or as pre-treatment before DM/Q (10/20 mg/kg, i.p.) on the seizure threshold of PTZ to
the onset to MC twitch (A) and THE (B). + P<0.05 in comparison with saline + DM/Q group (mean±S.E.M, n = 7).
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anticonvulsant effect of DM/Q in our study (Fig. 5A, B). The 5-HT1A
receptor is widely distributed throughout the CNS, both in pre- synaptic
and post-synaptic sites [31]. DM directly stimulates the post-synaptic 5-
HT1A receptor or indirectly increases 5-HT release from serotonergic
neurons [32]. Glutamate inhibits 5-HT release via stimulation of NMDA
receptors [33]. Therefore, it is reasonable to assume that DM can in-
crease the 5-HT release. Activation of the 5-HT1A receptor leads to
neuronal hyperpolarization [33]. Likely, WAY-100635 increases 5-HT
in the synaptic cleft by preferential inhibition of the pre-synaptic the 5-
HT1A auto-receptor. 5-TH induced neuronal hyperpolarization via ac-
tivation of the post-synaptic 5-HT1A receptor can potentiate the antic-
onvulsant effect of DM/Q. In this context, we have already reported
that WAY-100635 potentiated the anticonvulsant effect of the 5-HT1A
receptor agonist 8−OH-DPAT or selective serotonin reuptake (SSR)
inhibitor sertraline [14]. However, further investigations are needed on
the involvement of the 5-HT1A receptor in the anticonvulsant effect
DM/Q.
5. Conclusions
In conclusion, the results of this study show that adding quinidine
increases the anticonvulsant effect of low doses of DM, while attenuates
the anticonvulsant effect of high dose of DM. Our results suggest that
the effects of DM/Q on seizure activity is due to the elevation of DM
concentration, based on the earlier reports that the FDA- approved DM/
Q increases the ratio of DM to DX. Meanwhile, using ketamine, WAY-
100635, or BD-1047 we showed that NMDA receptor, sigma-1 receptor,
and 5-HT1A receptor are to some extent involved in the central effects of
DM/Q on seizure activity.
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